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Purgical Versus Percutaneous Occlusion
f Ostium Secundum Atrial Septal Defects
esults and Cost-Effective Considerations in a Low-Income Country
ladimiro L. Vida, MD, Joaquin Barnoya, MD, MPH, Mauricio O’Connell, MD, Juan Leon-Wyss, MD,
uis A. Larrazabal, MD, Aldo R. Castañeda, MD, PHD
uatemala City, Guatemala
OBJECTIVES We compared the effectiveness and cost of percutaneous occlusion using an Amplatzer septal
occluder (ASO) (AGA Medical Corp., Golden Valley, Minnesota) device compared with
surgical closure of an ostium secundum atrial septal defect (ASD II) in Guatemala.
BACKGROUND The percutaneous occlusion of ASD II in first-world nations seems to offer better clinical
results and lower cost compared with surgical closure.
METHODS We reviewed the clinical course of 111 patients referred to our institution for closure of
isolated ASD II. Successful closure was assessed immediately after the procedures and at 12
months. Actual hospital costs were calculated for every patient who underwent either of the
two procedures.
RESULTS Eighty-three patients with ASD II (75%) were selected for percutaneous occlusion with the
ASO device, and the remaining 28 patients (25%) underwent surgical closure. In the device
group, in 72 patients (86.7%) devices were successfully deployed. At immediate and
12-month follow-up, the complete closure rate was 87.5% (63 of 72 patients) and 97.2% (70
of 71 patients), respectively. In the surgical group, all patients had successful closure
immediately after the procedure and at 12 months. Surgical closure offered a 27% cost savings
in comparison with percutaneous occlusion (U.S. $3,329.50  $411.30 and U.S. $4,521.03 
$429.71; p  0.001, respectively). Cost of the device (U.S. $2,930.00) proved to be the main
cause for this difference.
CONCLUSIONS We confirmed the clinical advantages of percutaneous occlusion over surgical closure of ASD
II. However, percutaneous occlusion costs were higher compared with surgical closure. In
Guatemala, where health care resources are limited, ASD II closure with the ASO device did
not prove to be cost-effective. (J Am Coll Cardiol 2006;47:326–31) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.086American College of Cardiology Foundation
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astium secundum atrial septal defect (ASD II) is one of the
ost common congenital heart defects (CHDs), occurring
n 5% to 10% of children (1) and in 30% of adult patients
ith CHD (2,3). Surgical closure has been considered for
any years the gold standard treatment for patients with an
SD II. Operative mortality is low (0% to 3%) (4–6) and
ong-term survival is high (25-year survival of 92%) (7).
In 1976, King et al. (8) performed the first percutaneous
transcatheter) occlusion of an ASD II in patients using a
ouble umbrella device. Since then, the use of percutaneous
cclusion has increased significantly. The successful device
losure rate at 12 months’ follow-up has been reported to be
etween 92% and 100% (9–12).
The alleged advantages of percutaneous occlusion over
urgical closure include superior cosmetic results, the avoid-
nce of cardiopulmonary bypass (CPB) and its potential
dverse sequelae (13), a lower incidence of postoperative
omplications, and a shorter hospital stay. However, to our
nowledge, published data about the outcome and safety of
hese intracardiac prostheses are limited to a seven-year
ollow-up (9–11,14). Another proposed advantage of per-
From the Department of Pediatric Cardiovascular Surgery, Unidad de Cirugía
ardiovascular de Cardiovascular (UNICAR), Guatemala City, Guatemala.w
Manuscript received March 28, 2005; revised manuscript received May 27, 2005,
ccepted June 6, 2005.utaneous occlusion over surgical closure is its lower cost
between 0.7% and 36% less than surgical closure) (15–20),
elated in part because of a shorter hospital stay.
The research concerning cost benefits of percutaneous
cclusion is based on data from high-income nations such as
he U.S., Italy, United Kingdom, and Australia (15–19). To
he best of our knowledge there are no data available from
ow-income countries, where health care resources are
imited. Furthermore, these countries are especially in need
f this information to derive institutional policies.
The objective of this study is to compare the effectiveness
nd cost of percutaneous occlusion using an Amplatzer
evice with surgical closure of ASD II in Guatemala.
ETHODS
e reviewed the charts of 111 patients who were referred to
he Unidad de Cirugía Cardiovascular de Guatemala (UNI-
AR) for isolated ASD II closure. Inclusion criteria were a
eft-to-right shunt at the atrial level with pulmonary blood
ow/systemic blood flow of 1.5 or the presence of right
entricular volume overload. Exclusion criteria were an
stium primum and sinus venosus ASDs, including partial
nomalous pulmonary venous connections, and patients
ith other associated CHDs requiring surgical repair.
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January 17, 2006:326–31 Cost for Atrial Septal Defect ClosureTwo techniques for ASD II closure are currently available
t UNICAR: 1) percutaneous occlusion with an Amplatzer
eptal occluder (ASO) (AGA Medical Corp., Golden Val-
ey, Minnesota), or 2) conventional surgical closure on CPB.
The size of the ASD II and the distance of the defect
rom the coronary sinus, atrioventricular valves, and right
pper pulmonary vein (margins of the ASD) were preoper-
tively measured by transthoracic echocardiography. The
ize and margins of the ASD II were used as criteria to
elect patients either for percutaneous occlusion or surgical
losure. Any ASD II 38 mm in diameter and with
argins 4 mm was closed by the percutaneous approach,
hereas the remaining patients underwent surgical closure.
Percutaneous occlusion was conducted under general anes-
hesia with endotracheal intubation. Midazolam (0.1 mg/kg
ose) and ketamine (1 mg/kg dose) were used at the time of
nduction, and sevoflurane (0.5%) was administered for anes-
hesia maintenance. Vascular access was through the femoral
ein. The device used was the ASO. The ASO is a self-
entering device made of two flat discs of Nitinol (Mycrogroup
nc., Medway, Massachusetts) wire. A polyester mesh was
dded to the discs to enhance thrombogenicity. Device size
as selected based on ASD II dimension, which was measured
ith an Amplatzer balloon-sizing catheter using the stationary
alloon technique (within 2 mm of the balloon-stretched
iameter); available sizes range from 4 to 40 mm.
A transesophageal echocardiogram was obtained after
SO placement to verify its correct position and to detect
ny residual interatrial shunts. Afterward, patients were
ransferred directly to the ward and analgesia was achieved
ith ketorolac (1 mg/kg intravenously every 8 h). A single
ose of cefazolin (25 mg/kg intravenously) was used as pro-
hylactic antibiotic therapy. Patients were discharged home
ithin 24 h on aspirin (150 mg by mouth daily) for six months.
Surgical closure was achieved through a mid-line sternot-
my by using moderate hypothermia at 30°C, CPB aortic
ross-clamping, and cold crystalloid cardioplegic arrest. The
SD II was exposed though a right atriotomy and closed
ither directly or with a fresh autologous pericardial patch
depending on ASD size). Patients routinely were extubated
n the operating room and transferred to the intensive care
nit (ICU) for 24 h. Postoperative pain medications in-
luded morphine for the first 12 h (0.1 mg/kg dose) and
etorolac (1 mg/kg dose intravenously every 8 h). Cefazolin
25 g/kg intravenously every 6 h for 24 h) was used as
Abbreviations and Acronyms
ASD II  ostium secundum atrial septal defect
ASO  Amplatzer septal occluder
CHD  congenital heart disease
CPB  cardiopulmonary bypass
ICU  intensive care unit
UNICAR  Unidad de Cirugía Cardiovascular de
Cardiovascularrophylactic antibiotic therapy.
A
CAt discharge, all patients had a chest X-ray, a 12-lead
lectrocardiogram, and either an echocardiogram in the
urgical group or a transesophageal echocardiogram in the
evice group (immediately after the device was placed).
fter 12 months, a cardiologic work-up, including an
chocardiogram, was performed at UNICAR.
Complete ASD II closure was defined as no or minimal
esidual shunt at the interatrial level (color jet 1 to 2 mm,
ssessed by color Doppler echocardiogram). A residual
hunt at the interatrial level was defined as the presence of
color jet width 2 mm (19,21). Complications were
efined as early if they occurred while the patient was still in
he hospital and late after the patient had been discharged.
Actual hospital costs were calculated for every patient
ho underwent either of the two procedures used for ASD
I closure (22). Our cost-effective analysis compared only
he direct costs (patient care related) in relation to the
linical success of the two procedures. Table 1 lists the items
ncluded for each procedure.
To estimate the total cost for each patient, we multiplied
he unit cost of the various components of care by the
ocumented use and then summed the product. Medical,
ursing, and technical staff salaries were considered in the
otal cost of the procedure for every patient.
Results are presented as mean values and standard devi-
tion (median and range when data not normally distrib-
ted). Differences between mean and proportions were
ssessed with analysis of variance if the variable was contin-
ous or chi-square test if dichotomous (23). The Fisher
xact test was used in cases in which the sample size was
mall. Level of significance was set at p  0.05. To find a
% difference (19) in the success rate between the percuta-
eous and the surgical groups (97% and 100%, respectively),
ith a power of 80% and alpha of 0.05, we would need a
ample size of 866 patients (with continuity correction) to
nd this difference in percentages.
ESULTS
ighty-three of the 111 patients with ASD II (75%) were
elected for percutaneous occlusion with ASO device (de-
ice group), and the remaining 28 patients (25%) underwent
able 1. List of Items Included in the Total Costs for
ercutaneous and Surgical ASD II Closure
. Operating room/catheterization laboratory (includes salaries of all
personnel)
. Medications and materials used during anesthesia and
operation/procedure
. Length of intensive care unit stay (days)
. Hospitalization (days)
. Blood products
. Diagnostic and follow-up tests (echocardiogram, electrocardiogram,
chest X-ray)
. ASO device
. CPB equipmentSD IIOstium secundum atrial septum defect; ASO Amplatzer septal occluder;
PB  cardiopulmonary bypass.
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Cost for Atrial Septal Defect Closure January 17, 2006:326–31urgical closure (surgical group). Table 2 shows the demo-
raphic characteristics of both groups.
omparison of closure results. Of the 83 patients in the
evice group, 72 had devices successfully deployed (86.7%).
he 10 patients in whom the ASO devices were not
mplanted had been erroneously considered suitable candi-
ates based on transthoracic echocardiography. Device im-
lantation was not attempted in these 10 patients because
ndings on balloon sizing of their ASD II precluded
uccessful device implantation. The stretched diameter of
he ASD II was larger than the largest available ASO device
40 mm). In the 11th patient, the device embolized into the
ight ventricle after deployment and required surgical re-
oval. Of the 72 devices positioned successfully, mean size
as 28.20 mm (7.29). Sixty-three of the 72 patients (87.5%)
ad immediate complete closure of the ASD II, whereas at
2 months’ follow-up the complete closure rate was 97.2%
69 of 71 patients). Because of device displacement 20 days
fter deployment, one patient underwent surgical removal of
SO. This patient will be subsequently described.
In the surgical group, ASD II closure was achieved by
rimary suture closure in eight patients and with a fresh
ericardial (autologous) patch in 20 patients. Mean CPB
ime was 28.08 (7.29) min and mean aortic cross-clamp
ime was 14.67 (9.38) min. All patients in the surgical group
ad a successful closure immediately after the procedure and
t 12 months’ follow-up (Table 3).
able 2. Demographic and Baseline Data Between Successful
evice and Surgical Closure Groups
Device Group Surgical Group p Value
umber of patients 83 28
ge, yrs (SD) 18.3 (15.5) 7.14 (5.5) 0.0003
Interquartile range 6–27 3.5–10
emale (%) 67 29 0.001
SD II size,
mm (SD)
25.5 (8.2) 20.11 (9.4) 0.04
SD II  ostium secundum atrial septum defect.
Table 3. Comparison of Outcomes Between D
De
Total number of patients
Successful device deployment 72
Residual shunts at discharge 9
Residual shunts at 12 months’ follow-up 2
Early complications 3
Late complications 2
Blood products 2
Procedure time, min (SD) 18
Intensive care unit stay, days (SD)
Range
Total hospital days (SD)
Cost per cure, U.S. (SD) $4,78
Cost of ASO device in Guatemala, U.S. $
Cost per case, U.S. (SD) $4,52
*One patient underwent surgical removal of the ASO device
device displacement 20 days after deployment. †Fisher’s exact test;
ASO  atrial septal occluder.Three patients (4.1%) in the device group and three
atients (10.7%) in the surgical groups had early complica-
ions (p  0.4) (Table 3). Early complications in the device
roup included: 1) a device embolism after successful
eployment that required surgical removal (this patient was
o longer considered in the device group for further analy-
is); 2) an anaphylactic reaction to antibiotic; and 3) surgical
emoval of a defective ASO device (due to incomplete disk
pening) from the femoral vein. In the latter patient, the
SD II was closed during the same hemodynamic session
ith a new ASO device introduced through the contralat-
ral femoral vein. Early complications in the surgical group
ncluded a pleural effusion in two patients and a pneumo-
horax in one patient. All three patients required a chest
ube.
Late complications occurred in two patients (2.7%) of the
evice group; none occurred in the surgical group (Table 3).
n the device group, one patient presented with chest pain
nd cyanosis (transcutaneous arterial saturation of oxygen of
0%) at 20 days after occlusion. An echocardiogram re-
ealed downward dislodgement of the ASO device, which
irected the inferior vena cava blood flow into the left
trium. After a failed attempt to remove the device through
percutaneous approach, it was removed surgically, and the
SD II was closed at the same time. The other patient had
hest trauma 20 months after successful placement of a
9-mm ASO device. After the trauma, an echocardiogram
evealed two shunts (4 mm) within the fossa ovalis. Two
dditional ASO devices (16 and 24 mm) were placed to
cclude the new shunt areas. However, in one of the devices,
he two disks opened incompletely and had to be removed.
ubsequently, the patient underwent surgical removal of the
wo remaining ASO devices and surgical closure of the
SD II.
omparison of ICU and hospital stay. In the device
roup, 69 patients (95.8%) were immediately transferred to
he ward after device deployment (Table 3). Three patients
4.2%) were transferred to the ICU, two because of post-
and Surgical Closure Groups
roup Surgical Group p Value
28
86.7%) — —
12.5%) 0/28 (0%) 0.06†
2.8%) 0/28 (0%) 0.6†
4.1%) 3/28 (10.7%) 0.4
2.7%) 0 0.9†
2.7%) 13/28 (46.4%) 0.0001
80.4) 193.67 (32.5) 0.4
0.2) 1.75 (0.9) 0.0001‡
) (1–2.5)
0.6) 4.57 (1.0) 0.0001
$429.71) $3,329.5 ($411.30) 0.0001
.00 — —
$429.71) $3,329.5 ($411.30) 0.0001
ubsequent ostium secundum atrial septum defect closure forevice
vice G
83
/83 (
/72 (
/71* (
/72 (
/72 (
/72 (
0.50 (
0.05 (
(0–2
2.08 (
1.88 (
2,930
1.03 (
and s
‡Mann–Whitney rank-sum test.
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January 17, 2006:326–31 Cost for Atrial Septal Defect Closurerocedural complications and one because of a transient
ypotensive episode in the catheterization laboratory. All
atients in the surgical group were transferred to the ICU
Table 3).
Blood products were administered to two patients in the
evice group (2.7%) and in 13 patients in the surgical group
46.4%; p  0.0001) (Table 3). In the former group, blood
roducts were used because of anemia after the procedure.
n the latter group, blood products were used as part of the
lood prime for CPB in three patients. The remaining 10
atients were transfused in the ICU because of a postoper-
tive hematocrit of 24%.
Patients in the surgical group had a significantly longer
ospital stay than patients in the device group (p  0.0001)
Table 3). There were no hospital deaths in either of the two
roups, and all patients were discharged home in stable
linical condition.
omparison of costs. The mean cost (cost for cure) in the
evice group was higher compared with the cost in the
urgical group (p  0.0001) (Table 3). The main difference
n costs between the two groups was the cost of the ASO
evice, despite the fact that the surgical group had longer
CU and hospital stay and required more blood transfusions
p  0.0001) (Table 3).
ISCUSSION
ur data agree with previous reports of the use of the ASO
evice for percutaneous ASD II closure concerning safety
nd efficacy (14–20,24,25). There were no deaths in either
evice or surgical groups, and there were no statistical
ifferences in the incidence of postprocedure complications
etween the two groups. Worldwide, the ASO device has
een used since 1997 and, nowadays, it is an alternative to
urgical treatment, offering better cosmetic results, the
voidance of CPB, and a shorter hospital stay (9–12,24,26).
The initial limitations of percutaneous occlusion of an
SD II with a device, such as a very large (34 mm) or
ultiple occurrences of ASD II, or very young age of the
atients, have been overcome. Hence, this procedure is
onsidered in many centers as the treatment of choice for
SD II occlusion (10,12,27–30).
Although in our experience, patients in the surgical group
ere younger than in the device group, age was not
onsidered a selection criterion for either the percutaneous
cclusion or the surgical closure. The ASD II size was larger
n the device group than in the surgical group, which may be
ue in part to the older age of patients in this group.
Percutaneous device deployment failure has been re-
orted to be between 0% and 20% (12,14–17,19,20,24,31).
ailure rate at our institution was relatively high (11 of 83
atients; 13.2%). However, improving preprocedural echo-
ardiographic measurements of ASD II size and margins
hould significantly reduce this rate. pMean CPB time and mean aortic cross-clamp time were
tandard for this procedure (14,24). Residual early and late
trial shunts after surgical closure were rare (32,33).
At present, there are no long-term data available about
he device closure of ASD II. Midterm follow-up about the
omplete ASO device closure of ASD II (up to 4 years)
eport residual atrial shunts between 0% and 4% of patients
19,34,35).
In this study, there was a borderline statistical significant
ifference in the residual shunt immediately after the pro-
edure between the device and surgical groups. The fact that
e did not find a significant p value for this difference might
e the result of the small size of our sample (our study is
nderpowered). Regarding 12-month procedure success,
here was no statistical significant difference between the
wo study groups.
Data from the U.S., Europe, and Australia revealed either
imilar or lower costs (between 0.7% and 36% less) using the
ercutaneous approach in comparison with surgical closure
15–20). Difference was mainly due to avoidance of ICU
tay, a lower incidence of postprocedural complications, and
shorter hospital stay (15–20).
The Transition System, Inc. accounting system (Transi-
ion System Inc., Nashville, Tennessee, 1988) is a method
o estimate the average unit cost for various components of
ospital care, including direct and indirect costs, and it is
sed in the U.S. (15,20,22). Because the national health
ystem in Guatemala is not comparable with a U.S. health
aintenance organization-style system, the Transition Sys-
em Inc. system was not applicable for cost calculation in
his study.
Our analysis confirmed the described clinical advantages
f percutaneous occlusion of ASD II in comparison with
onventional surgical closure, including the avoidance of
CU stay, a shorter hospital stay, and lower use of blood
roducts.
However, in Guatemala, a low-income country, surgical
losure of a ASD II proved 31% cheaper (cost per cure) in
omparison with percutaneous occlusion (U.S. $3,329.50 
411.30 vs. U.S. $4,781.88  $429.71, respectively).
Even if we calculate the cost per case, without consid-
ring the additional cost for the initial percutaneous
roup of patients who underwent a catheterization but
id not receive a device, or patients who received a device
ut then embolized requiring surgical removal, the cost of
urgical closure is still 27% less than percutaneous closure
U.S. $3,329.50  $411.30 vs. U.S. $4,521.03 
429.71, respectively).
The reason for this difference is the cost of the ASO
evice in Guatemala, namely U.S. $2,930.00. This cost
epresents 65% of the total cost of transcatheter ASD II
cclusion with an ASO. The percutaneous approach with-
ut including the cost of the device is 52% less costly than
he surgical procedure. We found only two other published
eports (15,17) concerning the comparison of the two
rocedures for ASD II closure without taking into account
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Cost for Atrial Septal Defect Closure January 17, 2006:326–31he cost of the device. In both there was a similar cost
avings 50% in the interventional approach in comparison
ith the surgical closure.
According to our findings, in Guatemala, where health
are resources are limited, ASD II closure with the expen-
ive ASO device did not prove cost effective given our
educed institutional budget. Clearly, data on cost effective-
ess for ASD II closure from high-income countries are not
ransferable to low-income countries.
Our study has several limitations. Because UNICAR
oes not have the information needed to calculate cost of
very single medication used in the operating room and in
he catheterization laboratory, we included information
rovided by UNICAR of 10 randomly chosen patients from
ach of the two groups. Assuming that the use of medica-
ions remained constant for each procedure, this estimated
ean was added as a fixed cost to each patient in each
roup. Because this might not be always the case, costs
ight be underestimated (even though this would be
pplicable to both groups and it represents 10% of the
otal cost in both groups).
Nevertheless, our study provides data concerning cost
ffectiveness, comparing percutaneous occlusion with an
SO device versus surgical closure of ASD II in a low-
ncome country. Given these circumstances, resources have
o be judiciously allocated to the treatment that allows the
argest number of patients to be effectively treated.
eprint requests and correspondence: Dr. Vladimiro Vida,
epartment of Pediatric Cardiovascular Surgery, UNICAR, 9
venue, 8-00 zona 1, Guatemala City, 01011 Guatemala CA.
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